Farmas USA

GILD

Servidor... lamentablemente es la excepción en mi cartera de farmas... aunque mis no farmas KHC, ABI y LVMH hoy me han dado un buen día en el conjunto de mi cartera.

Joer,,,,y para los que compramos ayer INFI,,,,,nada????

Copio y pego algo sobre NVAX que me acaba de saltar en el programa: Es inicio de Fase 2, imagino que ya lo sabréis, pero me ha saltado con el mercado cerrado en el programa ahora mismo.

Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults
GAITHERSBURG, Md., Oct 22, 2015 (GLOBE NEWSWIRE via COMTEX) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 rollover clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults enrolled in the prior Phase 2 trial.
The trial is a randomized, observer-blinded, placebo-controlled rollover trial designed to enroll the same 1600 adults 60 years of age and older (older adults) who participated in the recently concluded prior Phase 2 trial. Participants previously randomized to receive 135ug RSV F Vaccine or placebo will be re-enrolled and re-randomized in the current trial to receive either 135ug RSV F Vaccine or placebo. This will result in analysis of four separate study arms: a) participants receiving RSV F Vaccine in both the first trial and second trial; b) participants receiving placebo in the first trial and RSV F Vaccine in the second trial; c) participants receiving RSV F Vaccine in the first trial and placebo in the second trial; and d) participants receiving a placebo in both the first trial and second trial.
The primary endpoints of the trial will evaluate safety and serum anti-F IgG antibody concentrations in response to immunization with the RSV F Vaccine. Secondary endpoints will examine palivizumab-competing antibody (PCA) concentration and neutralizing antibody titer to at least one RSV/A and one RSV/B strain.
"It is estimated that 2.4 million adults 65 years of age or older are infected with RSV annually in the U.S., leading to as many as 900,000 medical interventions and 14,000 deaths each year," said Stanley C. Erck, President and CEO. "This RSV F Vaccine rollover trial will provide important information on the amplitude and duration of immunogenicity in older adults, which will be a key data set as we develop the RSV F Vaccine for annual, seasonal vaccination."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[email protected]
240-268-2000

Russo Partners, LLC

David Schull [email protected]
Todd Davenport, Ph.D. [email protected]

212-845-4271

NVAX
Ya en 7 = + 5.58 % en AH
http://www.nasdaq.com/symbol/nvax/after-hours
Sin lugar a dudas que 6.50 es un muy buen soporte,

Ostras, espero que no afecte al posible inicio de la fase 3 de RSV en Ancianos y lo hagan en paralelo.    NVAX   edito: nada, nada ... fase prevista, nada de lo que preocuparse, es la vacuna de refuerzo

leñe, es que INFI no la llevo en watchlist y veo que si que debiera llevarla.

Feliciades tb , una gran lechuga verde en medio del desierto rojo ..

NVAX- Esos 7$ en AH no son relevantes zokatira. Es más seguramente es una operación hecha antes de cierre.
Aunque ya me gustaría que mañana empiece con esos 7$, ojala, pero de momento no son relevantes.
Saludos

Voy con movil, copio pego de un usano, resume muy bien el objetivo del trial inciado

"This re-dose trial is in support of making the RSV an annual shot similar to flu vaccine. So that means every year, they make $$$$$. Some vaccines, you take 1 shot, and you are good for 5-10 years. For RSV, it will be good for 1 year before it drops off the protective level. If they can show that re-dosing is possible, then this becomes an annual cash cow".

NVAX